

## Ursolic Acid from *Plantago major*, a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis

Therese Ringbom,<sup>†</sup> Laura Segura,<sup>†,‡</sup> Ylva Noreen,<sup>†</sup> Premila Perera,<sup>†</sup> and Lars Bohlin<sup>\*,†</sup>

Division of Pharmacognosy, Department of Pharmacy, Biomedical Centre, Uppsala University, Box 579, S-751 23 Uppsala, Sweden

Received March 11, 1998


A hexane extract of *Plantago major* was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (**1**). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC<sub>50</sub> value of 130 μM and a COX-2/COX-1 selectivity ratio of 0.6. The structural isomer oleanolic acid (**2**) was found to be less active than **1**, with an IC<sub>50</sub> value of 295 μM, but showed a similar selectivity ratio (0.8). Furthermore, no significant inhibition on COX-2 or COX-1 was observed by the triterpenoid, 18β-glycyrrhetic acid (**3**). The direct inhibitory effect of **1** and **2** on COX-2 catalyzed prostaglandin biosynthesis increased with preincubation, indicating a time-dependent inhibition, while the effect on COX-1 was found to be independent of preincubation time.

The discovery of a new cyclooxygenase (COX, prostaglandin endoperoxide H synthase, PGHS) isoenzyme, COX-2, has sparked a new surge of interest in this enzyme.<sup>1,2</sup> A selective COX-2 inhibitor is suggested to exhibit an anti-inflammatory effect, although with fewer gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs), since the constitutive COX-1 catalyzed biosynthesis of prostaglandins (e.g., in the gastric mucosa) is unaffected.<sup>1</sup> Under normal conditions, the level of constitutively expressed COX-2 is very low in most cells, but a 10- to 80-fold increase of COX-2 expression has been detected after induction by cytokines, growth factors, oncogenes, serum, and tumor promoters.<sup>1,2</sup> The increased production of prostaglandins, observed at acute and chronic inflammatory sites, as well as in transformed cells and in tumors, is thought to be partly due to an upregulation of COX-2.<sup>2,3</sup>

As part of a search for new COX-2 selective compounds of natural origin, the perennial herb *Plantago major* L. (Plantaginaceae) was subjected to bioactivity-directed fractionation, guided by a COX-2 catalyzed prostaglandin biosynthesis in vitro assay.<sup>4</sup> This plant was selected because it is well known in the traditional medicine of countries in Europe, Asia, Africa, and South America for its use in the treatment of inflammation and wounds.<sup>5–8</sup> Furthermore, an aqueous extract of *P. major* has been reported to exhibit antiinflammatory activity in several in vivo models,<sup>9</sup> where some of the observed activities have been suggested to correlate with an inhibition of COX-2.<sup>10</sup>

The isolation was focused on the hexane extract, which was found to be the most active extract of *P. major* and was presumed to contain triterpenoids. Particular interest was taken in triterpenoids, inasmuch as they are known to possess antiinflammatory, antiulcer, and antitumor effects.<sup>11,12</sup> The inhibitory effect of the structural isomers ursolic acid (**1**) and oleanolic acid (**2**) was investigated. Moreover, the triterpenoid analogue, 18β-glycyrrhetic acid (**3**), with the carbonyl at position 29 and an additional ketone group at position 11, was tested. Many plants containing **1**, **2**, and/or **3** have been used in traditional

medicine to treat inflammatory disorders, and the occurrence of **1** and **2** in *P. major* has been reported in previous phytochemical studies.<sup>11,13,14</sup> All of these three compounds are known to possess inhibitory effects on inflammation and on various stages of tumor development.<sup>11,14,15</sup> The antiinflammatory activity of **1** and **2** has been attributed to the inhibition of histamine release as well as lipoxygenase, COX, and complement activity.<sup>11</sup> In a recent publication by Suh et al., **1** and **2** were reported to exhibit no substantial suppression of the de novo formation of lipopolysaccharide induced COX-2.<sup>16</sup> There are two approaches to inhibit COX and prostaglandin production, either by blocking the upregulated COX mRNA expression (de novo synthesis) and the subsequent prostaglandin production, or by a direct inhibition of the enzyme activity, consequently by affecting the capacity to catalyze the prostaglandin biosynthesis.<sup>4,16</sup>



A limited number of natural products are reported to have been investigated on COX-2 inhibitory effects, and they were tested mostly on suppression of COX-2 mRNA expression, although a few were investigated on enzyme activity.<sup>16–25</sup>

Based on the activities mentioned, our aim was therefore to study the inhibitory effect on the COX-2 enzyme, of extracts of *P. major* by bioactivity-directed fractionation,

\* To whom correspondence should be addressed. Tel.: +46 18 4714492. Fax: +46 18 509101. E-mail: lars.bohlin@pharmacog.uu.se.

<sup>†</sup> Uppsala University.

<sup>‡</sup> On leave from the Unit of Pharmacology and Pharmacognosy, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain.

**Table 1.** IC<sub>50</sub> Values ( $\mu\text{M}$ ) and Calculated Selectivity Ratios (COX-2/COX-1 Ratio) of **1–3** and Reference Compounds on Inhibition of COX-2 and COX-1 Catalyzed Prostaglandin Biosynthesis, after 10 min of Preincubation

compound	IC <sub>50</sub> ( $\mu\text{M}$ )		COX-2/COX-1
	COX-2	COX-1	
ursolic acid	130	210	0.6
oleanolic acid	295	380	0.8
glycyrrhetic acid <sup>a</sup>			
NS-398 <sup>b</sup>	53	>100 <sup>c</sup>	<0.5
ibuprofen <sup>b</sup>	1030	18	60
naproxen <sup>b</sup>	1010	11	100
indomethacin <sup>b</sup>	165	1.4	120

<sup>a</sup> No significant inhibitory effect, when tested up to 425  $\mu\text{M}$ .<sup>b</sup> Data from Noreen et al.<sup>4</sup> <sup>c</sup> Maximum dissolved concentration.




as well as the inhibition of the triterpenoids **1**, **2**, and **3**, using a COX-2 catalyzed prostaglandin biosynthesis assay.

## Results and Discussion


A Soxhlet hexane extract of the entire plant of *P. major* was investigated by bioactivity-guided fractionation using a COX-2 catalyzed prostaglandin biosynthesis assay in vitro. The hexane extract was separated by medium-pressure liquid chromatography (MPLC) over silica gel followed by preparative TLC, which led to the isolation of ursolic acid (**1**) as the major active component. The structural identification was performed using FABMS and <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, by comparing the data to those previously reported for ursolic acid,<sup>26</sup> as well as to an authentic sample.

The inhibitory effects of ursolic acid (**1**), oleanolic acid (**2**), and 18 $\beta$ -glycyrrhetic acid (**3**) were further investigated by using authentic samples (Table 1). Compound **1** selectively inhibited COX-2 catalyzed prostaglandin biosynthesis, measured after a 10-min preincubation, with an IC<sub>50</sub> value of 130  $\mu\text{M}$ , compared with COX-1 derived prostaglandin synthesis, which showed an IC<sub>50</sub> value of 210  $\mu\text{M}$  (Figure 1). The resulting COX-2 selectivity was 0.6. Compound **2** inhibited COX-2 and COX-1 catalyzed prostaglandin biosynthesis, with IC<sub>50</sub> values of 295  $\mu\text{M}$  and 380  $\mu\text{M}$ , respectively (10-min preincubation), thereby exhibiting a COX-2/COX-1 selectivity ratio of 0.8 (Figure 2). Consequently, **1** is a more potent inhibitor of both COX-2 and COX-1, compared to **2**, although both compounds show similar COX-2 selectivity ratios. Interestingly, no significant inhibitory effect of **3** on COX-2 or COX-1 was detected, when tested at 100  $\mu\text{g}/\text{mL}$  (212  $\mu\text{M}$ ) and 200  $\mu\text{g}/\text{mL}$  (425  $\mu\text{M}$ ) after a 10-min preincubation. A comparison with COX-2/COX-1 selectivity ratios of some traditional NSAIDs and NS-398, a synthetic selective COX-2 inhibitor, obtained in the same assay system,<sup>4</sup> resulted in a rank order with NS-398 as the most COX-2 selective compound followed by **1**, **2**, ibuprofen, naproxen, and finally the most COX-1 selective, indomethacin (ratios <0.5, 0.6, 0.8, 60, 100, and 120, respectively).

The time-dependence inhibition of COX-2 and COX-1 catalyzed prostaglandin biosynthesis by **1** and **2** was evaluated by measuring with and without 10 min of preincubation of the enzyme and test compound. Both **1** and **2** showed an increased inhibitory effect toward COX-2 catalyzed prostaglandin biosynthesis with preincubation, while the effect on COX-1 was almost independent of preincubation time (Figures 3 and 4). Tested at 100  $\mu\text{g}/\text{mL}$  without preincubation, **1** was found to inhibit only COX-1, but due to the large increase in COX-2 inhibition with preincubation time, it inhibited COX-2 selectively after 10 min of preincubation (Figure 3). The same time-

**Figure 1.** Dose-response curves of ursolic acid (**1**) on inhibition of COX-2 (■) and COX-1 (□) catalyzed prostaglandin biosynthesis. Values represent mean  $\pm$  S.E.M. ( $n = 3-12$ ).**Figure 2.** Dose-response curves of oleanolic acid (**2**) on inhibition of COX-2 (■) and COX-1 (□) catalyzed prostaglandin biosynthesis. Values represent mean  $\pm$  S.E.M. ( $n = 6-15$ ).**Figure 3.** Preincubation time-dependence of inhibition (%) of COX-2 (filled) and COX-1 (unfilled) catalyzed prostaglandin biosynthesis by ursolic acid (**1**) tested at 100  $\mu\text{g}/\text{mL}$  (■, □) and 200  $\mu\text{g}/\text{mL}$  (●, ○) final concentrations. Values represent mean  $\pm$  S.E.M. ( $n = 5-9$ ).

dependent behavior was observed, although less pronounced, when tested at 200  $\mu\text{g}/\text{mL}$ . Oleanolic acid (**2**) demonstrated less time-dependent inhibition than ursolic acid (**1**), changing from about equal potency to more COX-2 selectivity, when tested at 100  $\mu\text{g}/\text{mL}$  (Figure 4). Moreover, the activity shifted from COX-1 active to more equipotent when measured at 200  $\mu\text{g}/\text{mL}$ . These results suggest that the behavior of **1** and **2** is similar to that of NS-398, which exhibited equal potency toward COX-2 and COX-1 when



**Figure 4.** Preincubation time-dependence of inhibition (%) of COX-2 (filled) and COX-1 (unfilled) catalyzed prostaglandin biosynthesis by oleanolic acid (**2**) tested at 100  $\mu\text{g/mL}$  (■, □) and 200  $\mu\text{g/mL}$  (●, ○), final concentrations. Values represent mean  $\pm$  S.E.M. ( $n = 5-9$ ).

measured without preincubation, but showed COX-2 selective inhibition when enzyme and inhibitor were preincubated for 10 min or more.<sup>27</sup> Further studies will be needed to elucidate fully the kinetic behavior of these two triterpenoids toward the two COX enzymes.

The triterpenoids ursolic acid (**1**), oleanolic acid (**2**), and 18 $\beta$ -glycyrrhetic acid (**3**) as well as the extracts of *P. major*, are known to possess antiinflammatory activities in vitro and in vivo.<sup>9,11,28,29</sup> Suh et al. have found that neither **1** nor **2** showed any substantial suppression on LPS-induced COX-2 mRNA expression (de novo formation) and the subsequent prostaglandin production, whereas some derivatives of **1** and **2** blocked the expression.<sup>16</sup> No change in COX-1 protein levels was observed for any of the compounds. Maybe the difference in inhibition of prostaglandin production, compared with our results, is due to methodological differences such as the use of RAW cells, compared to sheep placental cotyledons, as well as different protein and substrate concentrations, which are factors known to give differences in  $\text{IC}_{50}$  values.<sup>30</sup> Preliminary results indicate that a decreased  $\text{IC}_{50}$  value of **1** is obtained by using a lower protein concentration, which further supports the necessity of a standardized protein level (unpublished results). To compare the enzyme activity of **1** and **2** with our results is not possible, because Suh et al. neither have reported  $\text{IC}_{50}$  values of **1** and **2** nor compared their activity with a COX-2 selective reference compound. However, the results of Suh et al. indicate that **1** and **2** exhibit no suppression of the *de novo* formation of COX-2 mRNA,<sup>16</sup> and our results showed that both compounds inhibit COX-2 catalyzed prostaglandin biosynthesis at about the same magnitude as the COX-2 selective inhibitor, NS-398.

An inhibitory effect of **1-3** on carrageenan-induced rat-paw edema has been reported, and **2** also exhibits an inhibitory effect on adjuvant-induced arthritis in rats.<sup>28,29,31-33</sup> Also, the aqueous extract of *P. major* has been found to inhibit carrageenan-induced rat-paw edema and inflammation induced by croton oil in the air-pouch test using rats.<sup>9</sup> Interestingly, these three models have been used by Masferrer et al. to evaluate the role of COX-2 in inflammation in vivo.<sup>10</sup> The inflammation induced was shown to be due to induction of COX-2 in the cells, and subsequent prostaglandin production was blocked by NSAID administration. Therefore, our present results, where a hexane extract of *P. major* as well as **1** and **2** inhibited COX-2 catalyzed prostaglandin biosynthesis, may contribute to an explanation of the above-mentioned antiinflam-

matory activities in vitro and in vivo. Further studies are needed, however, to explain the opposing effect of **3**.

A therapeutic advantage, in relation to COX-2 inhibition of selective COX-2 inhibitors, is the low ulcer toxicity. Vane and Botting have suggested a parallel relationship between COX-2 selectivity and gastrointestinal side effects with NSAID treatment, such that COX-2 selective compounds cause fewer ulcers.<sup>1</sup> Compounds **1** and **3** have been reported to inhibit stress-induced ulceration in rats, and **2** has been shown to reduce chemically induced ulceration, produced, for example, by NSAIDs.<sup>34-36</sup> A decrease in stress-induced ulceration in rats by aqueous and methanol extracts of *P. major* has also been observed.<sup>37</sup> Recently, Masferrer et al. demonstrated that administration of COX-2 selective inhibitors did not produce stomach lesions, in contrast to administration of nonselective NSAIDs.<sup>10</sup>

It may be concluded that the previously reported anti-inflammatory and antiulcer effects of ursolic acid (**1**) and oleanolic acid (**2**) in vitro and in vivo can be partly explained by a selective time-dependent inhibition of the COX-2 enzyme activity. Moreover, our results indicate that **1** and **2** may be promising leads for further exploration of selective inhibitors of COX-2 catalyzed prostaglandin biosynthesis.

## Experimental Section

**General Experimental Procedures.** Positive ion FABMS were measured on a Finnigan 4021 instrument, with direct inlet (glycerol as matrix). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> on a Bruker DRX 400 NMR instrument (400 MHz) with TMS as internal standard. Analytical and preparative TLC were performed on precoated silica gel plates (DC-Alufolien, Kieselgel 60 F<sub>254</sub>, 0.2 mm, and DC-fertigplatten, Kieselgel 60, 0.5 mm, Merck, Darmstadt, Germany), with detection provided by UV light (254 and 366 nm) and by spraying with vanillin-sulfuric acid reagent followed by heating (120 °C). MPLC was performed with SEPARO MPLC equipment (Baeckström Separo AB, Lidingö, Sweden).<sup>38</sup> A SEPARO variable-length glass column, with an inner diameter of 1.5 cm, packed with silica gel 60, 40-63  $\mu\text{m}$  (Merck, Darmstadt, Germany), was used. A continuous gradient was afforded by a SEPARO constant-volume mixing chamber combined with an open reservoir. An FMI Lab pump, model QD (Fluid Metering Inc., Oyster Bay, NY) was used (flow rate 20 mL/min) and fractions (5 mL) were collected with a Gilson model 201 fraction collector. Column chromatography over Sephadex LH-20 (Pharmacia, Uppsala, Sweden) was used for final purification.

The source of COX-1 (prostaglandin endoperoxide H synthase-1, PGHS-1) was microsomes prepared from bovine seminal vesicles according to Noreen et al.<sup>4</sup> Purified COX-2 (prostaglandin endoperoxide H synthase-2, PGHS-2) was obtained from sheep placental cotyledons (Cayman Chemical Company, Ann Arbor, MI). Ursolic acid [3 $\beta$ -hydroxy-12-ursen-28-oic acid] (**1**), oleanolic acid [3 $\beta$ -hydroxy-12-oleanen-28-oic acid] (**2**), and 18 $\beta$ -glycyrrhetic acid [3 $\beta$ -hydroxy-11-oxo-18 $\beta$ -20 $\beta$ -olean-12-en-29-oic acid] (**3**) (Sigma, Stockholm, Sweden) as well as crude and semi-purified fractions were dissolved in 20% DMSO (4% of final concentration) and tested at 100  $\mu\text{g/mL}$  (final concentration). The maximum possible dissolved concentration of **1** and **2** in solvents in this assay was 800  $\mu\text{M}$  and 400  $\mu\text{M}$ , respectively.

**Plant Material.** Entire plants of *Plantago major* L. (Plantaginaceae) were collected in July 1997, in Uppsala, and identified by Dr. Inga Hedberg (Department of Systematic Botany, Uppsala University). A voucher specimen, coded AIP 97006, has been deposited at the Division of Pharmacognosy, Uppsala.

**Extraction and Isolation.** The dried and powdered plant material (29.1 g) was successively extracted in a Soxhlet apparatus with hexane (0.4 g), CH<sub>2</sub>Cl<sub>2</sub> (0.2 g), MeCN (0.7 g),

and H<sub>2</sub>O (7.7 g). All extracts were evaluated for inhibition of COX-2 catalyzed prostaglandin biosynthesis, where the hexane extract was found most active. The hexane extract was separated by MPLC. The extract (0.3 g) was dissolved in hexane (2.0 mL) and injected onto the SEPARO column (length 4.8 cm). The column was eluted with a continuous gradient from hexane, over toluene to MeOH and H<sub>2</sub>O. Initially, the mixing chamber contained 50 mL of hexane, and the reservoir, the first of the 13 premixed binary (less polar/more polar solvent) gradient mixtures, of 25 mL each, which were successively fed to the reservoir during separation. Fractions were combined according to TLC [toluene–MeOH (9:1) or CHCl<sub>3</sub>–MeOH–H<sub>2</sub>O (9:3:0.5)], yielding 15 fractions.

All fractions were tested for inhibition of both COX-2 and COX-1 catalyzed prostaglandin biosynthesis. Fraction 10 (11.5 mg) was found to inhibit COX-2 by 47% ±0.8 and COX-1 by 36% ±0.9, measured after 10 min of preincubation of enzyme and test compound, and fractions 10 and 11–13 (24 mg) were further purified by preparative TLC [toluene–MeOH (9:1)], yielding four fractions (A–D). Final purification of fraction A (5.6 mg) was performed by column chromatography over Sephadex LH-20 (CH<sub>2</sub>Cl<sub>2</sub>), yielding two fractions (A1–2). Fraction A2 (1.9 mg) showed 42% ±1.0 inhibition of COX-2 and 32% ±0.4 of COX-1 and was identified as ursolic acid (1).

**COX-1 and COX-2 Catalyzed Prostaglandin Biosynthesis Assay.** Experiments were performed as described previously by Noreen et al.<sup>4</sup> The inhibition of COX-catalyzed prostaglandin biosynthesis was calculated as the relative decrease in radioactivity (disintegrations per minute) of the samples containing test substance as compared to the solvent vehicle. IC<sub>50</sub> values were obtained by linear regression analysis, and values represent means ±S.E.M. of 2–5 experiments ( $n = 3–18$ ).

**Acknowledgment.** The authors are grateful to Rolf Andersson for recording NMR spectra; Suresh Gohil, for MS measurements; and Beatrice Nilsson, for skillful technical assistance. Financial support by the Swedish Council of Forestry and Agricultural Research is gratefully acknowledged.

## References and Notes

- Vane, J. R.; Botting, R. M. In *New Targets in Inflammation, Inhibitors of COX-2 or Adhesion Molecules*; Bazan, N., Botting, J., Vane, J., Ed.; Kluwer Academic: Dordrecht, 1996; Chapter 1, pp 1–12.
- Subbaramaiah, K.; Zakim, D.; Weksler, B. B.; Dannenberg, A. J. *Proc. Soc. Exp. Biol. Med.* **1997**, *216*, 201–210.
- Richardson, C.; Emery, P. *Drug Safety* **1996**, *15*, 249–260.
- Noreen, Y.; Ringbom, T.; Perera, P.; Danielson, H.; Bohlin, L. *J. Nat. Prod.* **1998**, *61*, 2–7.
- Samuelsen, A.-B.; Smestad Paulsen, B.; Wold, J. K.; Otsuka, H.; Yamada, H.; Espevik, T. *Phytother. Res.* **1995**, *9*, 211–218.
- Rombi, M.; Lecomte, A. *Precis de Phytomedicine*; Romart: Carros, 1993; p 104.
- Quisumbing, E., *Medicinal Plants of the Philippines*, Republic of Philippines Department of Agriculture and Natural Resources: Manila, 1951; pp 894–896.
- Watt, J. M.; Breyer-Brandwijk, M. G. *The Medicinal and Poisonous Plants of Southern and Eastern Africa*; E. & S. Livingstone: Edinburgh, 1962; pp 848–850.

- Núñez Guillén, M. E.; da Silva Emim, J. A.; Souccar, C.; Lapa, A. J. *Int. J. Pharmacog.* **1997**, *35*, 99–104.
- Masferrer, J. L.; Isakson, P. C.; Seibert, K. *Gastroent. Clin. N. Am.* **1996**, *25*, 363–372.
- Liu, J. *J. Ethnopharmacol.* **1995**, *49*, 57–68.
- Safayhi, H.; Sailer, E.-R. *Planta Med.* **1997**, *63*, 1–7.
- Newall, C. A.; Anderson, L. A.; Phillipson, J. D. *Herbal Medicines, Guide for Health-care Professionals*; The Pharmaceutical Press: London, 1996; pp 210–211.
- Shibata, S. In *Food Phytochemicals for Cancer Prevention*; Ho, C.-T., Ed.; ACS Symposium Series 547; American Chemical Society: Washington, DC, 1994; Chapter 31, pp 308–321.
- Hsu, H.-Y.; Yang, J.-J.; Lin, C.-C. *Cancer Lett.* **1997**, *111*, 7–13.
- Suh, N.; Honda, T.; Finlay, H. J.; Barchowsky, A.; Williams, C.; Benoit, N. E.; Xie, Q.-W.; Nathan, C.; Gribble, G. W.; Sporn, M. B. *Cancer Res.* **1998**, *58*, 717–723.
- Noreen, Y.; El-Seedi, H.; Perera, P.; Bohlin, L. *J. Nat. Prod.* **1998**, *61*, 8–12.
- Tao, X.; Schulze-Koops, H.; Ma, L.; Cai, J.; Mao, Y.; Lipsky, P. E. *Arthritis Rheum.* **1998**, *41*, 130–138.
- Glaser, K. B.; Lock, Y. W. *Biochem. Pharmacol.* **1995**, *50*, 913–922.
- Payá, M.; Ferrándiz, M. L.; Erradi, F.; Terencio, M. C.; Kijjoa, A.; Pinto, M. M. M.; Alcaraz, M. J. *Eur. J. Pharmacol.* **1996**, *312*, 97–105.
- Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Fong, H. H. S.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. *Science* **1997**, *275*, 218–220.
- Nanji, A. A.; Zakim, D.; Rahemtulla, A.; Daly, T.; Miao, L.; Zhao, S.; Khwaja, S.; Tahan, S. R.; Dannenberg, A. J. *Hepatology* **1997**, *26*, 1538–1545.
- Pang, L.; Hoult, J. R. S. *Biochem. Pharmacol.* **1997**, *53*, 773–782.
- Dirsch, V. M.; Kiemer, A. K.; Wagner, H.; Vollmar, A. M. *Eur. J. Pharmacol.* **1997**, *336*, 211–217.
- Mestre, J. R.; Subbaramaiah, K.; Sacks, P. G.; Schantz, S. P.; Tanabe, T.; Inoue, H. *Cancer Res.* **1997**, *57*, 1081–1085.
- Piozzi, F.; Paternostro, M.; Passannanti, S.; Gacs-Baitz, E. *Phytochemistry* **1986**, *25*, 539–541.
- Copeland, R. A.; Williams, J. M.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzaskos, J. M. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 11202–11206.
- Capasso, F.; Mascolo, N.; Autore, G.; Duraccio, M. R. *J. Pharm. Pharmacol.* **1983**, *35*, 332–335.
- Inoue, H.; Inoue, K.; Takeuchi, T.; Nagata, N.; Shibata, S. *J. Pharm. Pharmacol.* **1993**, *45*, 1067–1071.
- Pairet, M.; van Ryn, J.; Mauz, A.; Schierok, H.; Diederer, W.; Türk, D.; Engelhardt, G. In *Selective COX-2 Inhibitors, Pharmacology, Clinical Effects and Therapeutic Potential*; Vane, J., Botting, J., Ed.; Kluwer Academic and William Harvey: London, 1998; Chapter 3, pp 27–46.
- Kapil, A.; Sharma, S. *J. Pharm. Pharmacol.* **1995**, *47*, 585–587.
- Kosuge, T.; Yokota, M.; Sugiyama, K.; Mure, T.; Yamazawa, H.; Yamamoto, T. *Chem. Pharm. Bull.* **1985**, *33*, 5355–5387.
- Singh, G. B.; Singh, S.; Bani, S.; Gupta, B. D.; Banerjee, S. K. *J. Pharm. Pharmacol.* **1992**, *44*, 456–458.
- Snyckers, F. O.; Fourie, T. G. *EPO Bulletin* 83/45, 0 093 520 B1, 15.10.86, 1986.
- Gupta, M. P.; Nath, R.; Gupta, G. P.; Bhargava, K. P. *Indian J. Med. Res.* **1981**, *73*, 649–652.
- Dehpour, A. R.; Zolfaghari, M. E.; Samadian, T.; Kobarfard, F.; Faizi, M.; Assari, M. *Int. J. Pharm.* **1995**, *119*, 133–138.
- Yesilada, E.; Sezik, E.; Fujita, T.; Tanaka, S.; Tabata, M. *Phytother. Res.* **1993**, *7*, 263–265.
- Jirón, Z. *Approaching Optimal Conditions for Running Liquid Adsorption Column Chromatography Using Simple Computational Models*. Licentiate Thesis, Department of Chemistry, Organic Chemistry, Royal Institute of Technology: Stockholm, 1996.

NP9800881